{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T12:01:59Z","timestamp":1767960119081,"version":"3.49.0"},"reference-count":39,"publisher":"American Society for Microbiology","issue":"6","license":[{"start":{"date-parts":[[2000,6,1]],"date-time":"2000-06-01T00:00:00Z","timestamp":959817600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2000,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Tucaresol, a novel immunomodulator, was inactive against<jats:italic>Leishmania donovani<\/jats:italic>amastigotes in both peritoneal and bone marrow macrophages in vitro at concentrations between 100 and 1 \u03bcM, with toxicity to macrophages and parasites at 300 \u03bcM. However, against<jats:italic>L. donovani<\/jats:italic>in BALB\/c mice at doses between 80 and 1.25 mg\/kg of body weight administered once daily by the oral route during days 7 to 11 of infection, an optimal dose of 5 mg\/kg produced a 43.8 to 62.4% suppression of liver amastigotes, with significantly reduced activity at the extremes of the dose range. This response was not related to levels of infection. No interaction with the standard pentavalent antimonial sodium stibogluconate (Pentostam) was observed during this period of infection. The optimum dose of 5 mg\/kg was ineffective when administered during the first week of infection and was most effective against the liver infection when administered during weeks 2 to 3 of infection (42.3 to 46.8% inhibition) and against the splenic infection when administered during week 6 of infection (59.5% inhibition). The optimum dose of tucaresol against<jats:italic>L. donovani<\/jats:italic>in C57BL\/6 mice was 5 mg\/kg, which produced a 40.8 to 48.7% suppression of liver amastigotes when administered in a range of 80 to 1.25 mg\/kg during days 7 to 11 of infection. The drug had no activity against<jats:italic>L. donovani<\/jats:italic>infections in C.B-17<jats:italic>scid<\/jats:italic>mice when the same regimen was used.<\/jats:p>","DOI":"10.1128\/aac.44.6.1494-1498.2000","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T10:06:42Z","timestamp":1027764402000},"page":"1494-1498","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":33,"title":["Activity of the Novel Immunomodulatory Compound Tucaresol against Experimental Visceral Leishmaniasis"],"prefix":"10.1128","volume":"44","author":[{"given":"Aden C.","family":"Smith","sequence":"first","affiliation":[{"name":"<!--label omitted: 1-->Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London WC1E 7HT,1 and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Yardley","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London WC1E 7HT,1 and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Rhodes","sequence":"additional","affiliation":[{"name":"<!--label omitted: 2-->Glaxo Wellcome Research and Development, Medicines Research Centre, Stevenage, Herts SG1 2NY,2 United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon L.","family":"Croft","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London WC1E 7HT,1 and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","first-page":"270","DOI":"10.4269\/ajtmh.1985.34.270","article-title":"Enhancement of Glucantime therapy of murine Leishmania donovani infection by a synthetic immunopotentiating compound (CP-46,665-1).","volume":"34","author":"Adinolfi L. E.","year":"1985","unstructured":"Adinolfi L. E. Bonventre P. F. Enhancement of Glucantime therapy of murine Leishmania donovani infection by a synthetic immunopotentiating compound (CP-46,665-1). Am. J. Trop. Med. Hyg. 34 1985 270 277","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.48.2.409-416.1985"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.10.2.298"},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1046\/j.1365-2141.1996.d01-1744.x","article-title":"Tucaresol increases oxygen affinity and reduces haemolysis in subjects with sickle cell anaemia.","volume":"93","author":"Arya R.","year":"1996","unstructured":"Arya R. Rolan P. E. Wootton R. Posner J. Bellingham A. J. Tucaresol increases oxygen affinity and reduces haemolysis in subjects with sickle cell anaemia. Br. J. Haematol. 93 1996 817 821","journal-title":"Br. J. Haematol."},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0169-4758(92)90249-2"},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"53","DOI":"10.4269\/ajtmh.1982.31.53","article-title":"Cutaneous leishmaniasis in mice: resistance to glucan immunotherapy, either alone or combined with chemotherapy.","volume":"31","author":"Avila J. L.","year":"1982","unstructured":"Avila J. L. Biondo F. Monzon H. Convit J. Cutaneous leishmaniasis in mice: resistance to glucan immunotherapy, either alone or combined with chemotherapy. Am. J. Trop. Med. Hyg. 31 1982 53 59","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/infdis\/170.2.413","article-title":"Recombinant human granulocyte-macrophage colony-stimulating factor reverses neutropenia and reduces secondary infections in visceral leishmaniasis.","volume":"170","author":"Badaro R.","year":"1994","unstructured":"Badaro R. Nascimento C. Carvalho J. S. Badaro F. Russo D. Ho J. L. Reed S. G. Johnson W. D. Jr. Jones T. C. Recombinant human granulocyte-macrophage colony-stimulating factor reverses neutropenia and reduces secondary infections in visceral leishmaniasis. J. Infect. Dis. 170 1994 413 418","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0966-842X(98)01433-4","article-title":"Recent advances in identifying and validating drug targets in trypanosomes and leishmanias.","volume":"7","author":"Barrett M. P.","year":"1999","unstructured":"Barrett M. P. Coombs G. H. Mottram J. C. Recent advances in identifying and validating drug targets in trypanosomes and leishmanias. Trends Microbiol. 7 1999 82 88","journal-title":"Trends Microbiol."},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/clind\/24.4.684"},{"key":"e_1_3_2_11_2","first-page":"25","article-title":"Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries.","volume":"76","author":"Berman J. D.","year":"1998","unstructured":"Berman J. D. Badaro R. Thakur C. P. Wasunna K. M. Behbehani K. Davidson R. Kuzoe F. Pang L. Weerasuriya K. Bryceson A. D. M. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bull. W. H. O. 76 1998 25 32","journal-title":"Bull. W. H. O."},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1089\/jir.1996.16.321","article-title":"Killing of Leishmania donovani amastigotes by poly ICLC in hamsters.","volume":"16","author":"Bhakuni V.","year":"1996","unstructured":"Bhakuni V. Sigha U. K. Dutta G. P. Levy H. B. Maheshwari R. K. Killing of Leishmania donovani amastigotes by poly ICLC in hamsters. J. Interferon Cytokine Res. 16 1996 321 325","journal-title":"J. Interferon Cytokine Res."},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0020-7519(97)00169-0"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/301527a0"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1086\/314782"},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1093\/infdis\/168.4.986","article-title":"Mononuclear cell subpopulations and cytokine levels in human visceral leishmaniasis before and after chemotherapy.","volume":"168","author":"Cenini P.","year":"1993","unstructured":"Cenini P. Berhe N. Hailu A. McGinnes K. Frommel D. Mononuclear cell subpopulations and cytokine levels in human visceral leishmaniasis before and after chemotherapy. J. Infect. Dis. 168 1993 986 994","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.4049\/jimmunol.159.5.2274","article-title":"Convergence of Schiff base costimulatory signaling and TCR signaling at the level of mitogen-activated protein kinase ERK2.","volume":"159","author":"Chen H.","year":"1997","unstructured":"Chen H. Hall S. Heffernan B. Thompson N. T. Rogers M. V. Rhodes J. Convergence of Schiff base costimulatory signaling and TCR signaling at the level of mitogen-activated protein kinase ERK2. J. Immunol. 159 1997 2274 2281","journal-title":"J. Immunol."},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2165\/00063030-199707030-00005","article-title":"Potentiation of the immune system by Schiff base-forming drugs.","volume":"7","author":"Chen H.","year":"1997","unstructured":"Chen H. Hall S. Zheng B. Rhodes J. Potentiation of the immune system by Schiff base-forming drugs. Biodrugs 7 1997 217 231","journal-title":"Biodrugs"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.62.6.2649-2652.1994"},{"key":"e_1_3_2_20_2","first-page":"547","article-title":"Induction of delayed-type sensitivity to Leishmania parasite in a case of leishmaniasis cutanea diffusa with BCG and cord-factor (trehalose-6-6\u2032 dimycolate).","volume":"59","author":"Cohen H.","year":"1979","unstructured":"Cohen H. Induction of delayed-type sensitivity to Leishmania parasite in a case of leishmaniasis cutanea diffusa with BCG and cord-factor (trehalose-6-6\u2032 dimycolate). Acta Dermatovener. 59 1979 547 549","journal-title":"Acta Dermatovener."},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/0035-9203(88)90425-7","article-title":"Effect of cimetidine and 2\u2032-deoxyguanosine on the development of Leishmania mexicana in BALB\/c mice.","volume":"82","author":"Coleman R. E.","year":"1988","unstructured":"Coleman R. E. Edman J. D. Semprevivo L. H. Effect of cimetidine and 2\u2032-deoxyguanosine on the development of Leishmania mexicana in BALB\/c mice. Trans. R. Soc. Trop. Med. Hyg. 82 1988 232 233","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1002\/(SICI)1521-4141(199802)28:02<669::AID-IMMU669>3.0.CO;2-N","article-title":"Neutralization of IL-12 demonstrates the existence of discrete organ-specific phases in the control of Leishmania donovani.","volume":"28","author":"Engwerda C. R.","year":"1998","unstructured":"Engwerda C. R. Murphy M. L. Cotterell S. E. Smelt S. C. Kaye P. M. Neutralization of IL-12 demonstrates the existence of discrete organ-specific phases in the control of Leishmania donovani. Eur. J. Immunol. 28 1998 669 680","journal-title":"Eur. J. Immunol."},{"key":"e_1_3_2_23_2","first-page":"191","article-title":"Treatment of Mediterranean visceral leishmaniasis.","volume":"73","author":"Gradoni L.","year":"1995","unstructured":"Gradoni L. Bryceson A. Desjeux P. Treatment of Mediterranean visceral leishmaniasis. Bull. W. H. O. 73 1995 191 197","journal-title":"Bull. W. H. O."},{"key":"e_1_3_2_24_2","first-page":"237","article-title":"Leishmania mexicana in C3H mice: BCG and levamisole treatment of established infections.","volume":"41","author":"Grimaldi G. F.","year":"1980","unstructured":"Grimaldi G. F. Moriearty P. L. Hoff R. Leishmania mexicana in C3H mice: BCG and levamisole treatment of established infections. Clin. Exp. Immunol. 41 1980 237 242","journal-title":"Clin. Exp. Immunol."},{"key":"e_1_3_2_25_2","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/0014-5793(89)80222-4","article-title":"Drug targeting in Leishmania donovani infections using tuftsin-bearing liposomes as drug vehicles.","volume":"245","author":"Guru P. Y.","year":"1989","unstructured":"Guru P. Y. Agrawal A. K. Singha U. K. Singhal A. Gupta C. M. Drug targeting in Leishmania donovani infections using tuftsin-bearing liposomes as drug vehicles. FEBS Lett. 245 1989 204 208","journal-title":"FEBS Lett."},{"key":"e_1_3_2_26_2","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0928-8244(98)00079-0","article-title":"Influence of the host and parasite strain in a mouse model of visceral Leishmania infantum infection.","volume":"21","author":"Honore S.","year":"1998","unstructured":"Honore S. Garin Y. J.-F. Sulahian A. Gangneux J.-P. Derouin F. Influence of the host and parasite strain in a mouse model of visceral Leishmania infantum infection. FEMS Immunol. Med. Microbiol. 21 1998 231 239","journal-title":"FEMS Immunol. Med. Microbiol."},{"key":"e_1_3_2_27_2","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/0167-5699(95)80018-2","article-title":"Costimulation and the regulation of antimicrobial immunity.","volume":"16","author":"Kaye P. M.","year":"1995","unstructured":"Kaye P. M. Costimulation and the regulation of antimicrobial immunity. Immunol. Today 16 1995 423 427","journal-title":"Immunol. Today"},{"key":"e_1_3_2_28_2","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1080\/00034983.1995.11813016","article-title":"Strategies for immune intervention in visceral leishmaniasis.","volume":"89","author":"Kaye P. M.","year":"1995","unstructured":"Kaye P. M. Gorak M. Murphy M. Ross S. Strategies for immune intervention in visceral leishmaniasis. Ann. Trop. Med. Parasitol. 89 1995 75 81","journal-title":"Ann. Trop. Med. Parasitol."},{"key":"e_1_3_2_29_2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0022-1759(90)90334-R","article-title":"A modified colorimetric assay of macrophage activation for intracellular cytotoxicity against Leishmania parasites.","volume":"127","author":"Kiderlen A. F.","year":"1990","unstructured":"Kiderlen A. F. Kaye P. M. A modified colorimetric assay of macrophage activation for intracellular cytotoxicity against Leishmania parasites. J. Immunol. Methods 127 1990 11 18","journal-title":"J. Immunol. Methods"},{"key":"e_1_3_2_30_2","first-page":"402","article-title":"A novel immunopotentiating agent, tucaresol: results from a multicenter, pilot study in patients with metastatic melanoma.","volume":"38","author":"Kirkwood J. M.","year":"1997","unstructured":"Kirkwood J. M. Schuchter S. Donnelly S. Stover L. Drobins P. Whiteside T. L. Burnham J. P. Heitman C. K. Johnston J. M. A novel immunopotentiating agent, tucaresol: results from a multicenter, pilot study in patients with metastatic melanoma. Proc. Am. Assoc. Cancer Res. 38 1997 402","journal-title":"Proc. Am. Assoc. Cancer Res."},{"key":"e_1_3_2_31_2","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1086\/516482","article-title":"Endogenous interleukin-12 regulates acquired resistance in experimental visceral leishmaniasis.","volume":"175","author":"Murray H. W.","year":"1997","unstructured":"Murray H. W. Endogenous interleukin-12 regulates acquired resistance in experimental visceral leishmaniasis. J. Infect. Dis. 175 1997 1477 1479","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/157.5.973"},{"key":"e_1_3_2_33_2","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1084\/jem.185.5.867","article-title":"Behaviour of visceral Leishmania donovani in an experimentally induced T helper cell 2 (Th2)-associated response model.","volume":"185","author":"Murray H. W.","year":"1997","unstructured":"Murray H. W. Hariprashad J. Coffman R. L. Behaviour of visceral Leishmania donovani in an experimentally induced T helper cell 2 (Th2)-associated response model. J. Exp. Med. 185 1997 867 874","journal-title":"J. Exp. Med."},{"key":"e_1_3_2_34_2","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1172\/JCI114009","article-title":"Requirement for T cells and effect of lymphokines in successful chemotherapy for an intracellular infection. Experimental visceral leishmaniasis.","volume":"83","author":"Murray H. W.","year":"1989","unstructured":"Murray H. W. Oca M. J. Granger A. M. Schreiber R. D. Requirement for T cells and effect of lymphokines in successful chemotherapy for an intracellular infection. Experimental visceral leishmaniasis. J. Clin. Investig. 83 1989 1253 1257","journal-title":"J. Clin. Investig."},{"key":"e_1_3_2_35_2","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1073\/pnas.92.8.3142","article-title":"Switch from a type 2 to a type 1 T helper cell response and cure of established Leishmania major infection in mice is induced by combined therapy with interleukin 12 and Pentostam.","volume":"92","author":"Nabors G. S.","year":"1995","unstructured":"Nabors G. S. Afonso L. C. Farrell J. P. Scott P. Switch from a type 2 to a type 1 T helper cell response and cure of established Leishmania major infection in mice is induced by combined therapy with interleukin 12 and Pentostam. Proc. Natl. Acad. Sci. USA 92 1995 3142 3146","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"e_1_3_2_36_2","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1093\/jac\/14.5.463","article-title":"An in-vitro system for determining the activity of compounds against the intracellular amastigote form of Leishmania donovani.","volume":"14","author":"Neal R. A.","year":"1984","unstructured":"Neal R. A. Croft S. L. An in-vitro system for determining the activity of compounds against the intracellular amastigote form of Leishmania donovani. J. Antimicrob. Chemother. 14 1984 463 475","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_37_2","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/377071a0","article-title":"Therapeutic potentiation of the immune system by co-stimulatory Schiff-base-forming drugs.","volume":"377","author":"Rhodes J.","year":"1995","unstructured":"Rhodes J. Chen H. Hall S. R. Beesley J. E. Jenkins D. C. Collins P. Zheng B. Therapeutic potentiation of the immune system by co-stimulatory Schiff-base-forming drugs. Nature 377 1995 71 75","journal-title":"Nature"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.1997.56.522"},{"key":"e_1_3_2_39_2","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1093\/infdis\/170.3.659","article-title":"Successful treatment of refractory visceral leishmaniasis in India using antimony plus interferon.","volume":"170","author":"Sundar S.","year":"1994","unstructured":"Sundar S. Rosenkaimer F. Murray H. W. Successful treatment of refractory visceral leishmaniasis in India using antimony plus interferon. J. Infect. Dis. 170 1994 659 662","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_40_2","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1017\/S0031182097001017","article-title":"Validating targets for antiparasite chemotherapy.","volume":"114","author":"Wang C. C.","year":"1997","unstructured":"Wang C. C. Validating targets for antiparasite chemotherapy. Parasitology 114 1997 S31 S44","journal-title":"Parasitology"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.44.6.1494-1498.2000","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.44.6.1494-1498.2000","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,23]],"date-time":"2023-04-23T16:00:54Z","timestamp":1682265654000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.44.6.1494-1498.2000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,6]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2000,6]]}},"alternative-id":["10.1128\/AAC.44.6.1494-1498.2000"],"URL":"https:\/\/doi.org\/10.1128\/aac.44.6.1494-1498.2000","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,6]]},"assertion":[{"value":"1999-12-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2000-03-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2000-06-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}